Atai Beckley's shares closed at €6.30, just €0.45 away from Eli Lilly's fixed bid price. The spread reflects market skepticism about the deal's closure.
Atai Beckley shares closed on Friday at €6.30, down 0.79%, but have gained 71.2% over the last month. The catalyst for this surge is the friendly bid announced by Eli Lilly on July 16, which promises to pay $6.75 in cash for each share. This amount is supplemented by a contingent right worth up to $2.50 per share, linked to clinical and regulatory milestones of the BPL-003 and VLS-01 programs. In the best-case scenario, the deal could reach $3.8 billion.
However, the current share price, in euros, is very close to the fixed cash component. The risk premium has narrowed to reflect only the uncertainty regarding the approval of the bid and the opportunity cost until its closure, expected in the third quarter. Those buying today are not betting on the company's fundamentals, but on the likelihood that the deal will go through without setbacks.
Fundamental analysis offers contradictory signals. According to a Simply Wall Street report published on July 23, Atai Beckley only meets one of the six usual criteria for considering a stock cheap. The company trades at 13.4 times its book value, compared to the sector average of 2.5 times. Even compared to other acquisition candidates, whose average is around 22.6 times, Atai Beckley is at the high end of the range.
Analysts acknowledge that the agreement with Lilly and the FDA's favourable signals towards psychedelic therapies justify some of the enthusiasm. But they warn that the current price already discounts those factors significantly. The equation is clear: the stock's value depends on a narrative that, for now, rests on confidence in the bid's closure.
The necessary majority to greenlight the deal is not guaranteed. The voting agreements signed so far cover approximately 15% of the outstanding shares, but regulations require the backing of the majority of the total capital. This means that the current support block is insufficient on its own and that the deal will need to convince a significant number of independent shareholders.
To add uncertainty, several law firms specialising in shareholder rights have opened investigations. Halper Sadeh LLC, Ademi LLP, Kahn Swick & Foti, and Brodsky & Smith are examining whether Atai Beckley's board negotiated a fair price and followed an appropriate sales process. Halper Sadeh confirmed on July 21 that it is investigating possible violations of federal securities laws and fiduciary duties. These inquiries, while common in deals of this size, add an additional layer of risk that the market discounts in the spread between the stock price and the cash offer.
Since the announcement of the bid, several firms have adjusted their recommendations. H.C. Wainwright downgraded its rating from buy to neutral and set a target price of $7.50. Jefferies did the same, also with a target of $7.50. The reasoning is identical: the fixed bid price limits short-term upside potential, and the stock has become an arbitrage vehicle regarding the probability of closure.
However, the long-term outlook remains positive for those looking beyond the deal. Fourteen Wall Street analysts maintain a unanimous buy rating on the stock. H.C. Wainwright, in fact, reiterated a target of $25, arguing that the BPL-003 program for depression is in an advanced clinical phase and has intrinsic value. That price reflects what the company would be worth if a competing offer emerged or if the deal with Lilly failed.
The behaviour of the chart reinforces caution. The 52-week high of €7.85 reached on July 16 is 19.75% above the current close. The 14-day RSI stands at 74.4, clearly in overbought territory. The annualised volatility over 30 days is 85%, indicating sharp movements and elevated risk for retail investors.
For investors interested in this arbitrage opportunity, the current spread offers an annualised yield of around 15-20% if the bid closes within the expected timeframe. But any regulatory delay or an investigation questioning the price could widen the risk premium. The key will be the shareholders' meeting that must approve the deal and the FTC's decision after the Hart-Scott-Rodino waiting period.
You may also like
